• CT:VQ entered U.S. outpatient market via SimonMed Imaging agreement
• Operating revenue for FY26 was $7.2m, up 23%
• CT:VQ approved by TGA, contracts executed in Australia
• Completed acquisition of contextflow GmbH
• Published study in AJRCCM demonstrated CT:VQ's efficacy in lung surgery

4DMedical Ltd. released its Quarterly Activity Report and Appendix 4C for Q4 FY26, highlighting significant advancements. The company entered the U.S. outpatient market through a commercial agreement with SimonMed Imaging, marking a pivotal step in its U.S. expansion. Operating revenue for FY26 reached $7.2 million, a 23% increase from the previous period, driven by higher paid scan volumes, including CT:VQ scans, with strong margins exceeding 90%. 4DMedical's SaaS products are now deployed at 540 sites globally, a 39% increase year-over-year, achieving a record quarter with 105,970 scans. The company's strong cash balance stood at $278 million as of June 30, 2026. CT:VQ received approval from the Therapeutic Goods Administration (TGA), enabling commercial deployment in Australia. The company completed the acquisition of contextflow GmbH, expanding its European platform and adding lung cancer screening technologies. A study published in the American Journal of Respiratory and Critical Care Medicine demonstrated that CT:VQ-guided patient selection for lung volume reduction surgery achieved a 76% response rate, significantly higher than the current rate of 46%.

FY26 operating revenue $7.2m, up 23%; margins >90%; cash balance $278m

4DMedical anticipates continued growth with the expansion of CT:VQ in the U.S. and Europe, and the commercialization of its lung imaging solutions globally.